rosiglitazone has been researched along with HIV-Associated Lipodystrophy Syndrome in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (76.92) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carr, A; Cooper, DA; Emery, S; Hoy, J; Kelleher, A; Mallon, PW; Nolan, D; Rogers, G; Samaras, K; Sedwell, R; Unemori, P | 1 |
| Gmeinhardt, B; Haider, D; Ludvik, B; Pacini, G; Rieger, A; Schindler, K; Touzeau-Römer, V; Tura, A | 1 |
| Carr, A; Cooper, DA; Emery, S; Law, M; Samaras, K; Wand, H | 1 |
| Ackermans, M; Blümer, RM; Endert, E; Reiss, P; Sauerwein, HP; Serlie, MJ; van der Valk, M | 1 |
| Bejjani, DE; Harrill, D; Hileman, C; McComsey, GA; O'riordan, MA; Rizk, N; Ross, AC; Storer, N; Tungsiripat, M | 1 |
| Larson, RJ; Sheth, SH | 1 |
| Balasubramanyam, A; D'Amico, S; Jahoor, F; Patel, SG; Rehman, K; Sekhar, RV; Shi, J; Visnegarwala, F | 1 |
| Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP | 1 |
| Magkos, F; Mantzoros, CS | 1 |
| Díaz-Delfín, J; Domingo, P; Giralt, M; Villarroya, F; Wabitsch, M | 1 |
| Brathwaite, CE; Brebbia, JS; Fuhrer, J; Gelato, MC; McNurlan, MA; Mynarcik, DC; Quick, JL; Steigbigel, RT; Wax, MR | 1 |
| Häkkinen, AM; Halavaara, J; Järvinen, A; Ristola, M; Seppälä-Lindroos, A; Sutinen, J; Vehkavaara, S; Westerbacka, J; Yki-Järvinen, H | 1 |
| Ehrenborg, E; Fisher, RM; Funahashi, T; Hamsten, A; Kannisto, K; Korsheninnikova, E; Matsuzawa, Y; Nyman, T; Sutinen, J; Vidal, H; Virkamäki, A; Yki-Järvinen, H | 1 |
| Moyle, G; Sutinen, J | 1 |
| Baker, D; Carey, D; Carr, A; Cooper, DA; Emery, S; Law, M; Martin, A; Rogers, G; Samaras, K; Wand, H; Workman, C | 1 |
| Grinspoon, S; Hadigan, C; Havers, F; Sax, PE; Thomas, A; Yawetz, S | 1 |
| Cavalcanti, RB; Kain, KC; Raboud, J; Walmsley, S | 1 |
| Grunfeld, C; Lee, GA; Mafong, DD; Mauro, T; Tien, P; Yu, S | 1 |
| Mikhail, N | 1 |
| Carey, D; Carr, A; Cooper, DA; Emery, S; Feneley, MP; Kovacic, JC; Mallon, PW; Martin, A; Wand, H | 1 |
| Feldt, T; Häussinger, D; Kroidl, A; Kurowski, M; Oette, M; Sagir, A; Vogt, C; Wettstein, M | 1 |
| Carey, D; Carr, A; Cooper, DA; Emery, S; Martin, A; Rothwell, S; Wand, H | 1 |
| Feldt, T; Fritzen, R; Goebels, K; Häussinger, D; Kambergs, J; Kappert, G; Kroidl, A; Oette, M; Vogt, C; Wettstein, M | 1 |
| Cavalcanti, RB; Cheung, A; Kain, KC; Raboud, J; Shen, S; Walmsley, S | 1 |
| Crum, D; Grinspoon, S; Hadigan, C; Mazza, S | 1 |
1 review(s) available for rosiglitazone and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
15 trial(s) available for rosiglitazone and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Body Composition; DNA, Mitochondrial; Drug Administration Schedule; Fatty Acid-Binding Proteins; Female; Gene Expression Regulation; Heat-Shock Proteins; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Male; Mitochondria; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; RNA; RNA, Mitochondrial; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2008 |
The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Topics: Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Composition; Bone Density; Double-Blind Method; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2009 |
A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
Topics: Absorptiometry, Photon; Adiponectin; Adult; Antiretroviral Therapy, Highly Active; Body Composition; Calorimetry, Indirect; Double-Blind Method; Glucose; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed | 2009 |
Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cholesterol; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; PPAR gamma; Reverse Transcriptase Inhibitors; Rosiglitazone; Thiazolidinediones; Thymidine | 2010 |
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxybutyrates; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Netherlands; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Female; Glucose; Glucose Clamp Technique; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pilot Projects; Radiography; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Composition; Cholesterol; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Triglycerides | 2003 |
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
Topics: Adiponectin; Adipose Tissue; Antiretroviral Therapy, Highly Active; Body Composition; Fatty Acids; Gene Expression; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Liver; Proteins; Rosiglitazone; Subcutaneous Tissue; Thiazolidinediones | 2004 |
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Topics: Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Viral Load | 2004 |
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
Topics: Adiponectin; Adult; Double-Blind Method; Fatty Acids, Nonesterified; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Middle Aged; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Topics: Adult; Anti-HIV Agents; Australia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Vasodilation | 2005 |
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.
Topics: Anti-HIV Agents; Face; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Ultrasonography | 2005 |
Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Composition; Female; Glucose Tolerance Test; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Fat Distribution; CD36 Antigens; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2007 |
Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.
Topics: Adult; Female; Follow-Up Studies; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Particle Size; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
10 other study(ies) available for rosiglitazone and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.
Topics: Absorptiometry, Photon; Adipokines; Adult; Antiretroviral Therapy, Highly Active; Body Composition; Feeding Behavior; Glucose; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Lipid Metabolism; Male; Middle Aged; Rosiglitazone; Surveys and Questionnaires; Thiazolidinediones; Tomography | 2009 |
Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study.
Topics: Antiretroviral Therapy, Highly Active; Blood Glucose; Body Composition; Calorimetry, Indirect; Fatty Acids, Nonesterified; Glycerol; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Lipid Metabolism; Lipids; Lipolysis; Male; Mass Spectrometry; Middle Aged; Palmitates; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio | 2011 |
Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.
Topics: Adiponectin; Adipose Tissue; Antiretroviral Therapy, Highly Active; Dyslipidemias; Fatty Acids, Nonesterified; Glycerol; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Lipolysis; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2011 |
HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes.
Topics: Adipocytes; Adipogenesis; Cytokines; Gene Expression Regulation; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Inflammation; Resveratrol; Rosiglitazone; Sesquiterpenes; Stilbenes; tat Gene Products, Human Immunodeficiency Virus; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2012 |
Managing HIV lipoatrophy.
Topics: Anti-HIV Agents; Dideoxynucleosides; HIV-Associated Lipodystrophy Syndrome; Human Growth Hormone; Humans; Hypoglycemic Agents; Metabolic Syndrome; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Reverse Transcriptase Inhibitors; Rosiglitazone; Stavudine; Thiazolidinediones; Treatment Outcome | 2004 |
Summaries for patients. Rosiglitazone treatment for fat redistribution and metabolic abnormalities caused by anti-HIV therapy.
Topics: Adiponectin; Adult; Double-Blind Method; Fatty Acids, Nonesterified; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Middle Aged; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Rosiglitazone for HIV-1 lipoatrophy.
Topics: HIV-Associated Lipodystrophy Syndrome; Humans; Rosiglitazone; Thiazolidinediones | 2004 |
Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy.
Topics: HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin; Lipomatosis; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2004 |
Rosiglitazone for treatment of HIV lipodystrophy.
Topics: Cholesterol, HDL; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2004 |
Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Biological Availability; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Interactions; Drug Monitoring; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Rosiglitazone; Thiazolidinediones; Viral Load | 2005 |